A2A 252
Alternative Names: A2A-252; AO-252Latest Information Update: 08 Dec 2023
Price :
$50 *
At a glance
- Originator A2A Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein-protein interaction inhibitors; TACC3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
Most Recent Events
- 02 Nov 2023 Phase-I clinical trials in Fallopian tube cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy) in USA (PO) (NCT06136884)
- 02 Nov 2023 Phase-I clinical trials in Peritoneal cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy) in USA (PO) (NCT06136884)
- 02 Nov 2023 Phase-I clinical trials in Endometrial cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Monotherapy) in USA (PO) (NCT06136884)